7th Oct 2021 12:11
Fusion Antibodies PLC - Belfast-based therapeutic drug and diagnostic applications research organisation - Signs a new contract with undisclosed US-based biotechnology company, to receive minimum of USD1.8 million of fees over the next two years for a research and development project using affinity maturation platform RAMP. Framework for increased fee for service work depending on outcome of work undertaken. Undisclosed biotechnology company has already paid USD318,000 to Fusion upon signing.
In August, reported widened pretax loss in year to March 31 but cited ongoing investment in operations and research which are "expected to contribute towards future revenue growth".
Current stock price: 131.40 pence, up 17% on Thursday
Year-to-date change: up 6.0%
By Josie O'Brien; [email protected]
Copyright 2021 Alliance News Limited. All Rights Reserved.
Related Shares:
Fusion Antibodies